BioSpace News Archive

SP Industries, Inc., a Harbour Group company, acquired Irta Dosificacio I Technologia S.L. i-Dositecno (“i-Dositecno”), Jeff Fox, Harbour Group’s chairman and chief executive officer, announced today.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced today announced that it will host a conference call and audio webcast on Thursday, November 7, 2019 at 1:30 PM Pacific Time (4:30 PM Eastern Time) to report its third quarter 2019 financial results and provide corporate updates.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract for a preclinical investigation from its natural killer cell chimeric antigen receptor (CAR) program has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced the outcome of its two exploratory Phase 2 clinical studies evaluating the efficacy and safety of its once-daily oral and intravenous (IV) modernized tetracycline omadacycline in patients with two common forms of urinary tract infections (UTI).

Consumers Benefit from Doctor-Directed Clear Aligner Treatment with Superior Invisalign Technology and Proven Outcomes for Broadest Range and Scope of Malocclusion

Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2019 financial and operating results following the close of U.S. financial markets on Thursday, November 7, 2019.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) and Amgen (NASDAQ: AMGN) today announced a global strategic oncology collaboration for the commercialization and development in China of Amgen’s XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab), and the joint global development of 20 oncology assets in Amgen’s pipeline, with BeiGene responsible for development and commercialization in China.

Pendulum Therapeutics announced that the California Life Sciences Association has awarded it the 2019 Pantheon DiNA™ Award for Rising Star.

Eloxx Pharmaceuticals, Inc. (“Eloxx”), (NASDAQ: ELOX), today announced positive data demonstrating that ELX-02 results in a pronounced increase in both CFTR protein expression and mRNA stability further supporting its proposed mechanism of action, and that it was well tolerated with no serious adverse events in the Phase 1 program.

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its third quarter 2019 financial results before the market opens on Monday, November 4, 2019